News

From Stocks to Dollar, Trump’s ‘Golden Age’ Is Off to Ugly Start

(Bloomberg) -- When Donald Trump was sworn in as the 47th US president, he proclaimed the dawning of a new “Golden Age.” Most Read from BloombergNew York City Transit System Chips Away at Subway Fare EvasionNYC’s Congestion Toll Raised $159 Million in the First QuarterNewsom Says California Is Now the World’s Fourth-Biggest EconomyThe Last Thing US Transit Agencies Should Do NowAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryAround the 100-day mark of his second term, investors

S&P Global to separate its mobility division from parent to streamline business

The New York-based firm said its operations will consist of four core businesses after the separation – S&P Global Market Intelligence, S&P Global Ratings, S&P Global Commodity Insights and S&P Dow Jones Indices. "Separating Mobility will allow us to continue to focus on our core businesses and pursue our growth strategy," said Martina Cheung, President and CEO of S&P Global. S&P Global's first-quarter profit beat analysts' expectations, as demand for its data and analytics offerings remained robust amid economic turmoil.

Commvault Systems (NASDAQ:CVLT) Reports Bullish Q1, Stock Soars

Data backup provider Commvault (NASDAQ:CVLT) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 23.2% year on year to $275 million. Guidance for next quarter’s revenue was better than expected at $268 million at the midpoint, 1.8% above analysts’ estimates. Its non-GAAP profit of $1.03 per share was 11% above analysts’ consensus estimates.

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.4% year on year to $169.2 million. The company’s full-year revenue guidance of $707.5 million at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.39 per share was 11.4% above analysts’ consensus estimates.

Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.4% year on year to $169.2 million. The company’s full-year revenue guidance of $707.5 million at the midpoint came in 1% above analysts’ estimates. Its non-GAAP profit of $0.39 per share was 11.4% above analysts’ consensus estimates.